Discussing a T2D Medication That Could Reduce Insulin Needs in T1D

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/07/59/8b/07598b02-138a-1e92-767a-a6ad123b0f45/mza_3116404523087549397.jpg/600x600bb.jpg

Diabetes Discourse

ReachMD

202 episodes

1 month ago

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it comes to diabetes, glucose control is just the beginning.

Science

Medicine

RSS

All content for Diabetes Discourse is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Discussing a T2D Medication That Could Reduce Insulin Needs in T1D

Diabetes Discourse

1 year ago

Discussing a T2D Medication That Could Reduce Insulin Needs in T1D

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD

New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.